Although RAC/CDC42-specific inhibitors remain to be explored clinically, one FDA-approved non-steroidal anti-inflammatory drug (NSAID), R-ketorolac, has been shown to potently inhibit RAC1 and CDC42, and has been demonstrated to improve ovarian cancer patient survival (NCT02470299), suggesting that GTPase targeting could be efficacious in other human cancers with elevated expression and activity of RAC1 and/or CDC42 [299]. Here, CDC42 is linked to ovarian cancer.